Equities research analysts expect that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will post earnings per share (EPS) of ($0.92) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Protagonist Therapeutics’ earnings. Protagonist Therapeutics reported earnings of ($19.07) per share in the same quarter last year, which would suggest a positive year over year growth rate of 95.2%. The business is scheduled to announce its next earnings results on Thursday, September 21st.

According to Zacks, analysts expect that Protagonist Therapeutics will report full year earnings of ($3.74) per share for the current year. For the next financial year, analysts expect that the firm will report earnings of ($3.44) per share. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, May 10th. The company reported ($0.84) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.23.

PTGX has been the subject of several analyst reports. BMO Capital Markets raised their price target on shares of Protagonist Therapeutics from $34.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, May 31st. Zacks Investment Research upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 22nd.

COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Will Announce Earnings of -$0.92 Per Share” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/07/brokerages-expect-protagonist-therapeutics-inc-nasdaqptgx-will-announce-earnings-of-0-92-per-share-updated-updated-updated.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its stake in Protagonist Therapeutics by 17.8% in the fourth quarter. FMR LLC now owns 2,507,167 shares of the company’s stock valued at $55,133,000 after buying an additional 378,448 shares in the last quarter. State Street Corp raised its stake in Protagonist Therapeutics by 50.8% in the fourth quarter. State Street Corp now owns 92,163 shares of the company’s stock valued at $2,028,000 after buying an additional 31,042 shares in the last quarter. Teachers Advisors LLC raised its stake in Protagonist Therapeutics by 17.7% in the fourth quarter. Teachers Advisors LLC now owns 9,461 shares of the company’s stock valued at $208,000 after buying an additional 1,424 shares in the last quarter. Geode Capital Management LLC raised its stake in Protagonist Therapeutics by 1.9% in the first quarter. Geode Capital Management LLC now owns 101,218 shares of the company’s stock valued at $1,296,000 after buying an additional 1,850 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Protagonist Therapeutics by 15.1% in the first quarter. Bank of New York Mellon Corp now owns 26,148 shares of the company’s stock valued at $335,000 after buying an additional 3,433 shares in the last quarter. Hedge funds and other institutional investors own 47.57% of the company’s stock.

Shares of Protagonist Therapeutics (NASDAQ:PTGX) traded up 0.99% during midday trading on Friday, reaching $13.30. 30,689 shares of the company’s stock traded hands. Protagonist Therapeutics has a 52-week low of $8.00 and a 52-week high of $26.36. The stock has a 50-day moving average price of $10.80 and a 200-day moving average price of $14.24. The stock’s market cap is $224.18 million.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related stocks with our FREE daily email newsletter.